

## TITLE PAGE

### **Real-time IP-10 measurements as a new tool for inflammation regulation within a clinical decision support protocol for managing severe COVID-19 patients**

Shaul Lev<sup>1,2</sup>, Tamar Gottesman<sup>1,2</sup>, Gal Sahaf Levin<sup>1,2</sup>, Doron Lederfein<sup>3</sup>, Evgeny Berkov<sup>3</sup>, Dror Diker<sup>3</sup>, Aliza Zaidman<sup>3</sup>, Amir Nutman<sup>4</sup>, Tahel Ilan Ber<sup>5</sup>, Alon Angel<sup>5</sup>, Lior Kellerman<sup>5</sup>, Eran Barash<sup>5</sup>, Roy Navon<sup>5</sup>, Olga Boico<sup>5</sup>, Yael Israeli<sup>5</sup>, Michal Rosenberg<sup>5</sup>, Amir Gelman<sup>5</sup>, Roy Kalfon<sup>5</sup>, Einav Simon<sup>5</sup>, Noa Avni<sup>5</sup>, Mary Hainrichson<sup>5</sup>, Oren Zarchin<sup>5</sup>, Tanya M. Gottlieb<sup>5</sup>, Kfir Oved<sup>5</sup>, Eran Eden<sup>5\*</sup>, Boaz Tadmor<sup>1,2</sup>

<sup>1</sup> Intensive Care Unit, Rabin Medical Center, Hasharon, Petah Tikva, Israel

<sup>2</sup> Sackler Faculty of Medicine, Tel Aviv University, Israel

<sup>3</sup> Internal Medicine, Rabin Medical Center, Hasharon, Petah Tikva, Israel

<sup>4</sup> National Institute for Infection Control and Antibiotic Resistance, Tel Aviv Medical Centre, Tel-Aviv, Israel

<sup>5</sup>MeMed, Haifa, Israel

\*Corresponding author

The challenge of treating severely ill COVID-19 patients is particularly great due to the need to simultaneously manage oxygenation and the inflammatory state without compromising viral clearance. Currently, there are many tools to aid in oxygen management and in monitoring viral replication. However, predictive biomarkers for monitoring the host immune response across COVID-19 disease stages and specifically, for titrating immunomodulatory therapy are lacking. We utilized a recently cleared platform (MeMed Key™) that enables rapid and easy serial measurement of IP-10, a host protein implicated in lung injury due to viral-induced hyperinflammation. A dynamic clinical decision support protocol was employed for managing SARS-CoV-2 positive patients admitted to a COVID-19 dedicated medical center run by Clalit Health Services. This is the first protocol to include real-time measurements of IP-10 as a potential aid for regulating inflammation. Overall, 502 serial real-time IP-10 measurements were performed on 52 patients recruited between 7<sup>th</sup> April 2020 to 10<sup>th</sup> May 2020, with 12 patients admitted to the intensive care unit (ICU). IP-10 levels correlated with increased COVID-19 severity score and ICU admission. Within the ICU admitted patients, the number of days with IP-10 measurements >1,000 pg/ml was associated with mortality. Upon administration of corticosteroid immunomodulatory therapy, a significant decrease in IP-10 levels was observed. Real-time IP-10 monitoring represents a new tool to aid in management and therapeutic decisions relating to the inflammatory status of COVID-19 patients.

## INTRODUCTION

In the majority of SARS-CoV-2 positive patients, the host mounts a localized immune response sufficient to clear the virus from the lungs, following which the immune response recedes and the patient recovers.<sup>1</sup> In less than 15% of patients, a dysregulated immune response ensues, triggering multiple hyperinflammatory pathways involving a plethora of immune, endothelial, and other cell types.<sup>2,3</sup> The hyperinflammation involves a release of cytokines and chemokines creating a cytokine release syndrome, which has been implicated in acute lung injury, acute respiratory distress syndrome (ARDS), multiple organ failure and mortality.<sup>4-6</sup> The cytokine release syndrome resembles secondary hemophagocytic lymphohistocytosis and is characterized by increased interleukin (IL)-6, IL-2, IL-7, granulocyte colony stimulating factor, interferon- $\gamma$  induced protein 10 (IP-10, also known as CXCL-10), monocyte chemoattractant protein 1, macrophage inflammatory protein 1- $\alpha$ , and tumor necrosis factor- $\alpha$ .<sup>5,7</sup> Accumulating evidence points specifically to IP-10 as a marker for COVID-19 disease progression, with maintained high levels associated with mortality.<sup>8-13</sup> In various viral infection models, IP-10 is elevated<sup>14-17</sup> and implicated initially as promoting viral clearance,<sup>18</sup> but also, as an effector of immune-mediated acute lung injury, suggesting it plays a key role in both the normal and dysregulated responses to SARS-CoV-2 infection.<sup>19-21</sup> Accordingly, it has been proposed that IP-10 may represent a marker for COVID-19 disease progression as well as a therapeutic target for preventing lung injury.

The challenge of treating severely ill COVID-19 patients is particularly great due to the need to simultaneously manage oxygenation and the inflammatory state without compromising viral clearance (Figure 1). Accordingly, although accumulating evidence supports suppressing the immune system in severe COVID-19 patients in order to mitigate the cytokine release syndrome,<sup>22</sup> there is also a concern that over-suppression may reduce the immune system's capacity to respond effectively to the virus and increase susceptibility to secondary infections.<sup>23</sup> Corticosteroids in general and methylprednisolone in particular are strong non-specific immunomodulatory agents and their use in severe COVID-19 patients is the topic of ongoing debate and clinical research.<sup>22,23</sup> Currently, several tools are available for guiding therapeutic decisions on oxygenation and viral replication, but actionable biomarkers for monitoring the host-pathogen interaction and ensuing inflammatory responses are lacking. Clinical monitoring of IP-10 has been restricted in the absence of a rapid diagnostic test. MeMed Key™ is a novel platform recently cleared to provide IP-10 measurements in 15 minutes.

We developed a clinical decision support protocol aimed at achieving 3 predefined therapeutic goals: improving oxygen delivery, controlling inflammation, and promoting viral clearance. Based on our hypothesis that real-time IP-10 measurements can support detection and continuous monitoring of patients with a dysregulated immune response and potentially allow personalized corticosteroid regimens to improve patient outcome, we included longitudinal observation of IP-10 levels in the protocol as a potential tool to aid in inflammation control.

## METHODS

### Study Design

The prospective study included a cohort of SARS-CoV-2 positive patients recruited at a COVID-19 dedicated medical center (n = 52). An additional retrospective study was conducted to enable comparison of IP-10 levels across other acute respiratory infections (n = 182) and healthy subjects (n = 98).

## Patient population

### *COVID-19 patients*

The prospective study included 52 SARS-CoV-2 positive patients recruited at a COVID-19 dedicated medical center managed by Clalit Health Services, the second largest Health Management Organization worldwide. All SARS-CoV-2 positive inpatients at the site between 7<sup>th</sup> April 2020 to 10<sup>th</sup> May 2020 to whom the clinical decision support protocol was applied were recruited to the study. IRB approval was obtained and informed consent was waived as biomarker measurements were performed on serum remnants from routine blood draws. NCT number: NCT04389645. ARDS and its severity were defined according to the Berlin definition.<sup>24</sup>

### *Patients with other respiratory viruses*

A retrospective analysis was performed on a cohort of adult patients (n = 182) pooled from 2 studies, Curiosity<sup>14</sup> (NCT01917461) and Observer (NCT03011515) who fulfilled all of the following inclusion criteria: meet inclusion/exclusion criteria of original study; detection of at least one of the following viruses (human rhinovirus [HRV], respiratory syncytial virus [RSV], Influenza A [Flu A], Influenza B [Flu B], human coronavirus [HCoV]); and adjudication as viral infection by an expert panel (no bacterial detection).

### *Healthy subjects*

A retrospective analysis was performed on a cohort of adult patients (n = 98) from Curiosity<sup>14</sup> (NCT01917461) and Observer (NCT03011515) who were afebrile with no apparent infectious disease.

## Clinical decision support protocol

An overview of the clinical decision support protocol is provided in Figure 1. In brief, to manage oxygenation, PaO<sub>2</sub>/FiO<sub>2</sub> (P/F, ratio of arterial oxygen partial pressure to fractional inspired oxygen) was monitored twice daily and positive end-expiratory pressure (PEEP) titration was made based on cardiac output measurements when indicated. All patients received high dose N-acetylcysteine and bromohexin inhalations in order to induce mucolysis and prevent sticky secretion and atelectasis. Intra-tracheal injected surfactant was an option as a compassionate therapy for refractory hypoxemic ventilated patients.

Echocardiography and bedside Doppler ultrasound were ordered when pulmonary emboli or deep vein thrombosis were clinically suspected and when D-dimer levels significantly increased. Troponin levels were measured daily and electrocardiogram measurements were performed routinely to detect QT prolongation.

All ICU patients received 40 mg twice daily of enoxaparin. D-dimers were measured daily and the enoxaparin dose was adjusted up to 60 mg twice daily when D-dimer levels increased significantly. In case of proven thrombosis (as visualized by imaging), full anti-coagulation therapy was recommended. When minor bleeding occurred, sub-cutaneous heparin was administered. All ICU patients considered as hyperinflammatory were administered a total tocilizumab dosing of 800 mg, given in 2 separate doses of 400 mg, 12 hours apart. The following parameters were considered as reflective of a hyperinflammatory state: C-reactive protein (CRP) > 90 mg/l, ferritin >500 ng/dl, and IP-10 >1,000 pg/ml. All hyperinflammatory ICU patients were administered methylprednisolone or equivalent dosing of another corticosteroid; basic dosing was 1.5 mg/kg divided into 3 doses. Patients on hemodialysis who were hyperinflamed had access to cytokine removal hemodialysis (Theranova dialyzer).

The anti-viral therapy was based on combinations of hydroxychloroquine, azithromycin, zinc, and lopinavir/ritonavir at the discretion of the infectious disease consultant and was discussed daily.

Patients who did not show clinical improvement were given convalescent plasma divided into two doses as a compassionate therapy.

Compassionate Remdesivir became available at the end of April 2020. It was given to only one patient for a total of 7 days (200 mg loading dose followed by 100 mg maintenance dose from day 2 onwards) and was stopped as a result of elevated liver function tests.

### **Laboratory procedures**

Blood was collected serially from 52 patients as part of routine blood draw into serum separating tubes (SST). Serum was separated within 2 hours of collection and the fresh serum samples were measured on the MeMed Key™ (MeMed, Israel) rapid immunoassay platform that provides measurements of 3 immune system proteins (IP-10, CRP, and TNF-related apoptosis inducing ligand [TRAIL]), in 15 minutes, based on MeMed BV™ (MeMed, Israel) testing cartridges. Any unused serum was frozen at -20°C for up to one week and then transferred for storage at -80°C.

Frozen serum was used to determine retrospectively blood concentrations of IL-6. Measurements were performed using 'Quantikine human IL-6' (R&D systems, MN, USA) ELISA assay kits. Due to high IL-6 concentrations, each serum sample was diluted 1:4 and 1:40 with RD6F calibrator diluent supplied in the kits. Results were averaged when the difference in concentration between the 2 dilutions was <20%, otherwise the dilution in the linear range of the calibration curve was taken. Measurements were performed using an Absorbance Microplate Reader Sunrise and Magellan program (Tecan life science Grödig, Austria).

SARS-CoV-2 positivity was determined by RT-PCR (Seegene Inc, South Korea).

### **Statistical analysis**

Continuous variables are reported as median (interquartile range). Values for 2 related variables were compared using Mann-Whitney-U test (for continuous values) and Fisher's Exact test (for discrete values). Steroid dosage was converted to methylprednisolone equivalent dosage, using MedCalc's Steroid Conversion Calculator.<sup>25</sup> The analysis was performed using Python 3.7.6.

## **RESULTS**

### **Patient population**

Overall, 502 serial blood draws were sampled from 52 SARS-CoV-2 patients that were admitted to the COVID-19 dedicated medical center between 7<sup>th</sup> April 2020 and 10<sup>th</sup> May 2020 and included in the cohort study, with 12 admitted to the ICU. The median age of the 52 patients was 69, 69% were male, 23% were ventilated, 4 died. There was low in-ICU mortality (1 death, 8%) and non-pulmonary organ failure (0%); the 90-day mortality for ICU patients was 25% (3 deaths). The most common comorbidities were diabetes (42%) and hypertension (46%) (Table 1).

Among the 12 ICU patients, 10 needed invasive mechanical ventilation and exhibited a pulmonary status compatible with severe ARDS (Table 2). Of these, 7 were weaned during their ICU stay and transferred to a rehabilitation center, 1 was transferred to a respiratory rehabilitation center (Patient #5) and 2 (Patients #3 and #9) were transferred to the internal medicine department, where patient #3 died. 8 patients developed secondary bacterial infection (Table 2).

### **IP-10 levels indicate hyperinflammation and associate with mortality**

A dynamic clinical decision support protocol that includes IP-10 was employed for managing the SARS-CoV-2 patients admitted to the COVID-19 dedicated medical center (Figure 1). Based on an evolving understanding of the complex host-pathogen interaction during disease progression, the goals of this protocol were to improve oxygen delivery and control inflammation without

compromising viral clearance. Observations relating to improving oxygen delivery are described in the Supplementary material.

To assess IP-10 levels in SARS-CoV-2 infection as compared to other viral infections and healthy subjects, a retrospective analysis was performed that included cohorts from previous studies (Figure 2). IP-10 levels are increased in patients with viral infections versus healthy subjects ( $p < 0.001$ ). Among the viral infections, IP-10 levels are higher when the infection is associated with pulmonary pathology (RSV, Flu A, Flu B, HCoV, and SARS-Cov-2), versus non-pulmonary pathology (HRV;  $p < 0.02$ ). Moreover, among the SARS-CoV-2 positive patients, IP-10 is elevated greatly in ICU versus non-ICU patients ( $p < 0.019$ ).

Focusing on the prospective cohort of 52 SARS-CoV-2 positive patients, IP-10  $> 1,000$  pg/ml correlated with increased COVID-19 severity score<sup>5</sup> ( $p < 0.01$ ) and ICU admission ( $p < 0.05$ ; Supplementary Table 1). Among the 12 ICU patients, 11 were considered hyperinflammatory, and 10 received tocilizumab and methylprednisolone; patient #18 was admitted to the ICU after pneumothorax surgery and was not administered tocilizumab (Table 2). For COVID-19 patients ( $n = 52$ ) and the sub-group of ICU patients ( $n = 12$ ), the number of days with IP-10  $> 1,000$  pg/ml was associated with mortality (Figure 3). In contrast, the number of days with CRP  $> 90$  mg/l or ferritin  $> 500$  mg/dl was not associated with mortality (Supplementary Figure 1). Overall, 3 ICU patients died; patient #3 died of candidemia. Focusing on the remaining 2 ICU patients who died, IP-10  $> 1,000$  pg/ml was exhibited for an average of 7.5 days (standard deviation [SD], 2.1 days) in contrast to the 9 surviving patients who exhibited IP-10  $> 1,000$  pg/ml for an average of 1 day (SD, 1.1 day;  $p = 0.04$ ).

All ICU patients exhibited reduced IP-10 levels within 3 days of their first corticosteroid treatment administered in the ICU (Figure 4). In the case where patients were given additional corticosteroids a decrease in IP-10 levels was observed (Figure 5); patients #8 and #11 who exhibited multiple days of highly elevated IP-10 died. Retrospective examination of IL-6 levels in the ICU patients revealed a weak correlation with IP-10 levels (Pearson correlation coefficient, 0.26) and no association with mortality, both for number of days with IL-6  $> 80$  pg/ml or IL-6  $> 100$  pg/ml (Supplementary Figure 2).

### **TRAIL levels flag viral persistence**

The MeMed Key™ platform is also cleared to provide measurements of the immune protein TRAIL. Applying the formal criterion of two negative SARS-CoV-2 PCR tests as confirmation of viral clearance, eight out of the 12 ICU patients were clear of the virus within the study period. TRAIL  $\leq 25$  pg/ml was associated with longer duration of SARS-CoV-2 positivity ( $p = 0.012$ ). The number of days TRAIL  $\leq 25$  pg/ml was found to correlate with the number of virus positive days (Pearson correlation coefficient, 0.7).

## **DISCUSSION**

This is the first study to examine the potential utility of rapid and serial IP-10 measurements as a tool within a clinical decision support protocol aimed at improving oxygen delivery and controlling inflammation without increasing susceptibility to secondary infections or compromising viral clearance. The study was prompted by the need for additional, specific tools to monitor and assess COVID-19 patient inflammatory status. There is mounting evidence that aberrantly high IP-10 levels play a role in the acute lung injury that is observed in COVID-19 patients and that abnormally elevated IP-10 contributes to mortality. In line with this emerging understanding of the participation of IP-10 in the complex and multi-factorial COVID-19 pathophysiology, we found that IP-10 levels are associated with disease severity and reflect the patient's response to corticosteroids. Specifically, we

observed that relapsing surges of abnormally elevated IP-10 expression were characteristic of the patients that subsequently died, possibly due to more extensive lung damage. These findings suggest that longitudinal and real-time IP-10 measurements could help with personalizing immunomodulatory treatment regimens for COVID-19 patients and may support better patient outcomes.

Our clinical decision support protocol was developed in parallel to the Yale New Haven YNHHS treatment algorithm (latest version June 22)<sup>26</sup> and the Massachusetts General Hospital COVID-19 treatment guidance (June 24).<sup>27</sup> Similar to our protocol, the latest YNHHS algorithm recommends interventions to address oxygenation, inflammation, and viral clearance. Notably, in the YNHHS algorithm for hospitalized adult patients with severe disease, it is recommended that a cytokine panel be conducted on ICU admission and steroids be given at the discretion of the primary team. We propose that the information provided by multiple IP-10 measurements performed using an easy and rapid measurement platform, as opposed to a one-time cytokine panel, serves as actionable and dynamic support to steroid treatment decision-making by the primary team.

Currently, the non-specific inflammatory biomarkers CRP and ferritin are employed to detect and assess the inflammatory status of COVID-19 patients. IP-10 represents a complementary tool that has the added advantage of rapidly indicating response to even a single dose of corticosteroid therapy, enabling its use as an aid to personalize corticosteroid treatment regimens. In addition, unlike CRP and ferritin, IP-10 exhibited a strong correlation with mortality for the ICU patients, likely reflecting its purported role as an effector of acute lung injury in COVID-19 disease progression. Of note, this study did not include many COVID-19 patients at early stages of disease progression. We hypothesize that serial measurement of IP-10 levels in such patients may flag those who are transitioning to the hyperinflamed state and enable early initiation of corticosteroids in this subset of SARS-CoV-2 positive patients. Further studies are warranted to address this premise directly. Another marker used to monitor inflammation is IL-6, which is the therapeutic target of tocilizumab. Its use as an indicator of inflammatory status may be constrained when the patients are under tocilizumab therapy.<sup>28</sup> In line with previous reports, we did not find that IL-6 expression is an indicator of mortality.<sup>23</sup>

A recent meta-analysis including 24 observational studies from across the world (Asia, Europe, and North America) involving 10,150 COVID-19 patients demonstrated a combined in-ICU mortality of 41.6% (95% confidence interval [CI], 34.0-49.7%). We did not observe non-pulmonary organ failure and the in-ICU mortality rate was 8%. The main limitation of our study is that the study design was not a randomized controlled trial, which limits the ability to estimate the magnitude of improvement in patient outcome that is attributable to implementation of the dynamic clinical decision support protocol. Moreover, the cohort study design does not allow evaluation of the contribution of different elements of the protocol, in particular, the personalized corticosteroid regimens. In addition, this is a single-center study; application of the protocol at additional sites and across multiple cohorts is warranted. The pivotal strength of our study is that it is the first prospective investigation of the potential value of serial and rapid IP-10 measurements as an indicator of the inflammatory status of COVID-19 patients. In addition, preliminary data was collected suggesting that low TRAIL levels, reported as an indicator of infection severity<sup>29</sup>, when sustained may flag failure to clear the virus. Further studies of TRAIL and its prognostic value are required.

In conclusion, our study supports the utility of using serial and rapid IP-10 measurements as a practical new tool in management of COVID-19 patients. Future studies are warranted to establish the contribution of IP-10 within a clinical decision support protocol to improved COVID-19 patient outcome.

## REFERENCES

1. Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. *Nat. Rev. Immunol.* (2020) doi:10.1038/s41577-020-0311-8.
2. Cummings, M. J. *et al.* Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *MedRxiv Prepr. Serv. Health Sci.* (2020) doi:10.1101/2020.04.15.20067157.
3. Clinical management of COVID-19. <https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19>.
4. Ye, Q., Wang, B. & Mao, J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J. Infect.* (2020) doi:10.1016/j.jinf.2020.03.037.
5. Mehta, P. *et al.* COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet* **395**, 1033–1034 (2020).
6. McGonagle, D., Sharif, K., O'Regan, A. & Bridgewood, C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. *Autoimmun. Rev.* 102537 (2020) doi:10.1016/j.autrev.2020.102537.
7. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* **395**, 497–506 (2020).
8. Yang, Y. *et al.* Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. *J. Allergy Clin. Immunol.* (2020) doi:10.1016/j.jaci.2020.04.027.
9. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* **395**, 1054–1062 (2020).
10. Spinelli, F. R., Conti, F. & Gadina, M. Hijacking SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. *Sci. Immunol.* **5**, (2020).
11. Vaninov, N. In the eye of the COVID-19 cytokine storm. *Nat. Rev. Immunol.* **1** (2020) doi:10.1038/s41577-020-0305-6.
12. Chi, Y. *et al.* Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China. *J. Infect. Dis.* doi:10.1093/infdis/jiaa363.
13. Wang, J., Jiang, M., Chen, X. & Montaner, L. J. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. *J. Leukoc. Biol.* (2020) doi:10.1002/JLB.3COVR0520-272R.
14. Oved, K. *et al.* A Novel Host-Proteome Signature for Distinguishing between Acute Bacterial and Viral Infections. *PLoS ONE* **10**, e0120012 (2015).

15. van Houten, C. B. *et al.* A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. *Lancet Infect. Dis.* (2016) doi:10.1016/S1473-3099(16)30519-9.
16. Ashkenazi-Hoffnung, L. *et al.* A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study. *Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol.* (2018) doi:10.1007/s10096-018-3261-3.
17. Srugo, I. *et al.* Validation of a Novel Assay to Distinguish Bacterial and Viral Infections. *Pediatrics* e20163453 (2017) doi:10.1542/peds.2016-3453.
18. Lindell, D. M., Lane, T. E. & Lukacs, N. W. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. *Eur. J. Immunol.* **38**, 2168–2179 (2008).
19. Ichikawa, A. *et al.* CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. *Am. J. Respir. Crit. Care Med.* **187**, 65–77 (2013).
20. Tsai, C.-F., Chen, J.-H. & Yeh, W.-L. Pulmonary fibroblasts-secreted CXCL10 polarizes alveolar macrophages under pro-inflammatory stimuli. *Toxicol. Appl. Pharmacol.* **380**, 114698 (2019).
21. Lang, S. *et al.* CXCL10/IP-10 Neutralization Can Ameliorate Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Rats. *PLoS One* **12**, e0169100 (2017).
22. The cytokine storm and COVID-19 - Hu - - Journal of Medical Virology - Wiley Online Library. <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26232>.
23. Garcia, P. D. W. *et al.* Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. *EClinicalMedicine* **0**, (2020).
24. ARDS Definition Task Force *et al.* Acute respiratory distress syndrome: the Berlin Definition. *JAMA* **307**, 2526–2533 (2012).
25. MedCalc: Steroid Equivalence Converter. <http://www.medcalc.com/steroid.html>.
26. Yale New Haven Health | Clinical Resources. <https://www.ynhhs.org/patient-care/covid-19/for-employees/for-employees.aspx>.
27. COVID-19 Treatment Guidance. *Massachusetts General Hospital* <https://www.massgeneral.org/news/coronavirus/treatment-guidance>.
28. Calabrese, C., Rajendram, P., Sacha, G. & Calabrese, L. Practical aspects of targeting IL-6 in COVID-19 disease. *Cleve. Clin. J. Med.* (2020) doi:10.3949/ccjm.87a.ccc018.
29. Peteranderl, C. & Herold, S. The Impact of the Interferon/TNF-Related Apoptosis-Inducing Ligand Signaling Axis on Disease Progression in Respiratory Viral Infection and Beyond. *Front. Immunol.* **8**, 313 (2017).

TABLES

Table 1: Demographics of COVID-19 patients (total n = 52), non-ICU (n = 40) and ICU (n = 12)

		All (n=52)	Non ICU (n=40)	ICU (n=12)	p-value	
General	Age	68.6 (16.7)	66.4 (20.0)	70.2 (13.2)	0.313	
	Female	16 (31.0%)	15 (38.0%)	1 (8.0%)	0.078	
Smoking Status	Smoker	3 (6.0%)	3 (8.0%)	0 (0.0%)	1	
Other	Death	4 (8.0%)	1 (2.0%)	3 (25.0%)	0.034	
	Discharged	51 (98.0%)	39 (98.0%)	12 (100.0%)	1	
	Highest Temp	37.4 (1.2)	37.3 (0.9)	38.3 (0.9)	<0.001	
	Duration of Hospitalization	11.0 (13.5)	9.0 (7.5)	26.5 (12.2)	<0.001	
	Ventilated	12 (23.0%)	2 (5.0%)	10 (83.0%)	<0.001	
	Time Ventilated	0.0 (0.0)	0.0 (0.0)	15.0 (11.0)	<0.001	
	Co-infection	Bacterial Infection	10 (19.0%)	2 (5.0%)	8 (67.0%)	<0.001
Fungal Infection		4 (8.0%)	0 (0.0%)	4 (33.0%)	0.002	
Conditions	Diabetes	22 (42.0%)	16 (40.0%)	6 (50.0%)	0.74	
	Cardiovascular Disease	9 (17.0%)	7 (18.0%)	2 (17.0%)	1	
	Cerebrovascular Disease	3 (6.0%)	3 (8.0%)	0 (0.0%)	1	
	Dyslipidemia	9 (17.0%)	6 (15.0%)	3 (25.0%)	0.415	
	Hypertension	24 (46.0%)	18 (45.0%)	6 (50.0%)	1	
	Hypothyroidism	6 (12.0%)	2 (5.0%)	4 (33.0%)	0.021	
	Malignancy	5 (10.0%)	2 (5.0%)	3 (25.0%)	0.074	
	Obesity (BMI>30 kg/m2)	9 (17.0%)	8 (20.0%)	1 (8.0%)	0.666	
Symptoms	Sore Throat	1 (2.0%)	1 (2.0%)	0 (0.0%)	1	
	Sputum Production	1 (2.0%)	1 (2.0%)	0 (0.0%)	1	
	Weakness	12 (23.0%)	11 (28.0%)	1 (8.0%)	0.253	
	Rhinorrhea	1 (2.0%)	1 (2.0%)	0 (0.0%)	1	
	Chest pain	2 (4.0%)	2 (5.0%)	0 (0.0%)	1	
	Diarrhea	6 (12.0%)	6 (15.0%)	0 (0.0%)	0.316	
	Dyspnea	23 (44.0%)	17 (42.0%)	6 (50.0%)	0.746	
	Fever	29 (56.0%)	18 (45.0%)	11 (92.0%)	0.007	
	Loss of Taste and Smell	5 (10.0%)	5 (12.0%)	0 (0.0%)	0.578	
	Cough	26 (50.0%)	17 (42.0%)	9 (75.0%)	0.097	
	Markers	AST (GOT) (u/l) (max)	37.0 (38.8)	28.4 (25.5)	86.0 (91.2)	<0.001
		ALT (GPT) (u/l) (max)	34.2 (70.1)	28.6 (27.0)	120.1 (147.1)	<0.001
		Glucose (mg/dl) (max)	153.5 (129.6)	126.4 (85.1)	247.0 (76.9)	<0.001
LDH (u/l) (max)		610.0 (347.5)	500.0 (244.5)	912.5 (263.8)	<0.001	
Lymph.abs (K/micl) (min)		0.8 (0.7)	0.8 (0.7)	0.4 (0.4)	0.003	
Neu.abs (K/micl) (max)		5.6 (5.6)	5.0 (3.0)	13.8 (6.2)	<0.001	
PLT (10 <sup>3</sup> ) (min)		186.5 (111.8)	228.0 (123.5)	139.5 (49.8)	0.001	
PaO2/FiO2 (min)		83.0 (56.5)	141.0 (0.0)	80.5 (42.0)	<0.001	
Troponin (max)		19.5 (44.5)	11.5 (18.5)	69.5 (55.5)	<0.001	
Urea (max)		46.3 (40.6)	37.2 (27.5)	105.0 (66.9)	<0.001	
Ferritin (max)		595.0 (1022.8)	462.0 (459.2)	1691.5 (916.8)	<0.001	
D-Dimer (max)		1319.0 (4050.0)	1140.0 (1377.5)	7235.5 (18598.2)	<0.001	
Creatinine (mg/dl) (max)		1.0 (0.4)	0.9 (0.4)	1.0 (0.5)	0.086	
Total Bilirubin (mg/dl) (max)		0.5 (0.5)	0.5 (0.4)	0.9 (0.5)	0.001	
Total Protein (g/dl) (max)		7.0 (0.7)	7.0 (0.6)	7.0 (0.8)	0.136	
CRP (max)		97.9 (122.8)	95.0 (92.1)	158.4 (172.6)	0.04	
Scores		COVID-19 severity	26 (50.0%)	14 (35.0%)	12 (100.0%)	0
	qSOFA (on admission)	0.0 (1.0)	0.0 (1.0)	1.0 (1.2)	0.003	
Treatments	Methylprednisolone	12 (23.0%)	1 (2.0%)	11 (92.0%)	<0.001	
	Hydrocortisone	10 (19.0%)	4 (10.0%)	6 (50.0%)	0.006	
	Methylprednisolone+Prednisone+Hydrocortisone	22 (42.0%)	10 (25.0%)	12 (100.0%)	0	
	Renal Replacement Therapy	2 (4.0%)	1 (2.0%)	1 (8.0%)	0.412	
	Remdesivir	1 (2.0%)	0 (0.0%)	1 (8.0%)	0.231	
	Prednisone	6 (12.0%)	6 (15.0%)	0 (0.0%)	0.316	
	Nitric Oxide	5 (10.0%)	0 (0.0%)	5 (42.0%)	<0.001	
	ECMO	1 (2.0%)	0 (0.0%)	1 (8.0%)	0.231	
	Vasopressors	11 (21.0%)	2 (5.0%)	9 (75.0%)	<0.001	
	Convalescent Plasma	7 (13.0%)	3 (8.0%)	4 (33.0%)	0.041	
	Azithromycin	35 (67.0%)	24 (60.0%)	11 (92.0%)	0.076	
	Antiviral Lopinavir/Ritonavir	7 (13.0%)	1 (2.0%)	6 (50.0%)	<0.001	
	Antiviral Hydroxychloroquine plus Azithromycin	33 (63.0%)	22 (55.0%)	11 (92.0%)	0.037	
	Antiviral Hydroxychloroquine	36 (69.0%)	24 (60.0%)	12 (100.0%)	0.01	
	Antibiotics	30 (58.0%)	19 (48.0%)	11 (92.0%)	0.008	
	Tocilizumab	13 (25.0%)	3 (8.0%)	10 (83.0%)	<0.001	
	Days Under Systemic Corticosteroids	0.0 (6.2)	0.0 (0.2)	7.5 (7.5)	<0.001	
First BV Test	TRAIL	56.6 (35.4)	64.0 (27.4)	33.8 (12.9)	0.001	
	CRP	70.9 (85.4)	77.8 (70.1)	36.0 (166.8)	0.5	
	IP-10	596.3 (1213.1)	502.3 (895.8)	1642.2 (2155.8)	0.019	

**Table 1 Legend:** BMI, Body mass index; AST, Aspartate transaminase; AL, Alanine transaminase; LDH, Lactate dehydrogenase; Lymph. Abs, Absolute lymphocytes; Neu. Abs, Absolute neutrophils; PLT, platelets; PaO<sub>2</sub>/FiO<sub>2</sub>, Ratio of arterial oxygen partial pressure to fractional inspired oxygen; ECMO, Extracorporeal membrane oxygenation; qSOFA, quick sequential organ failure assessment; TRAIL, TNF-related apoptosis inducing ligand; IP-10, interferon-γ induced protein 10 (also known as CXCL-10); CRP, C-reactive protein; BV Test, serum measurement of TRAIL, CRP and IP-10 performed using MeMed Key™.


**Table 2:** Status of the 12 ICU patients

ICU patient #		1	2	3	4	5	6	7	8	9	11	18	38	
ICU patient status	Age	48	69	76	63	61	46	71	76	68	76	73	84	
	Sex	Male	Male	Male	Male	Male	Male	Male	Male	Male	Female	Male	Male	
	Hypertension	no	no	yes	no	yes	no	no	no	yes	yes	yes	yes	
	Diabetes	no	no	yes	no	yes	yes	no	no	yes	yes	no	yes	
	Days in ICU	21	27	17	16	19	18	38	35	14	21	3	4	
	Secondary bacterial coinfection	no	yes	yes	yes	no	yes	yes	yes	yes	yes	no	no	
	Mortality	no	no	yes	no	no	no	no	yes	no	yes	no	no	
Improve O <sub>2</sub> delivery	Guidance tools	Echocardiography	yes	no	yes	no	no	yes	yes	yes	no	yes	no	no
		D-Dimer > 10,000 ng/ml	yes	no	yes	no	no	no	yes	yes	yes	yes	no	no
		US/CT	no	no	no	no	no	no	yes	no	no	no	yes	no
		Troponin > 14 ng/l	yes	yes	yes	yes								
	Intervention	Nitric Oxide	yes	no	yes	no	no	yes	no	yes	no	yes	no	no
		Prone	yes	yes	yes	no	no	yes	yes	yes	no	yes	no	no
		Invasive mechanical ventilation	yes	yes	no	no								
		Fluids	yes	yes	no	yes	yes	yes	yes	yes	yes	yes	yes	yes
		Vasopressor therapy	no	yes	yes	no	no							
		ECMO	yes	no	no	no	no							
		Enoxaparin	yes	yes	yes	yes								
		Heparin	yes	yes	no	yes	no	yes	yes	yes	yes	yes	no	no
		TPA	no	no	yes	no	no	no	no	no	no	no	no	no
Control inflammation	Guidance tools	Ferritin > 500 mg/dl*	yes	yes	yes									
		CRP > 90 mg/l*	no	yes	yes	no	no	no	yes	yes	yes	yes	yes	
	Intervention	IP-10 > 1,000 ng/ml*	no	yes	no	yes	yes	no	no	yes	yes	yes	yes	
		Tocilizumab	no	yes	yes	no	yes							
Viral clearance	Guidance tools	Corticosteroids	yes	yes	yes									
		PCR (viral load)**	yes	yes	no	no	yes	yes	yes	yes	yes	no	yes	no
	Intervention	TRAIL level < 25 pg/ml*	no	yes	yes	yes	no	no	no	yes	no	yes	no	yes
		Zinc	no	no	yes	no	no	yes	yes	no	yes	no	no	no
		Lopinavir/Ritonavir	no	yes	no	yes	yes	no	no	yes	no	yes	yes	no
		Remdesivir	no	yes	no	no								
		Hydroxychloroquine	yes	yes	yes	yes								
		Azithromycin	no	yes	yes	yes	yes							
Convalescent Plasma	no	yes	no	no	no	no	no	yes	no	yes	no	yes		
*At any time point														
**Two negative PCR tests within study period														

**Table 2 Legend:** ICU, Intensive care unit; US, Ultrasound; CT, Computed tomography; ECMO, Extracorporeal membrane oxygenation; TPA, Tissue plasminogen activator; PCR, polymerase chain reaction.


## FIGURES

**Figure 1:** Overview of dynamic clinical decision support protocol employed for managing SARS-CoV-2 patients admitted to a COVID-19 dedicated medical center (Rabin Medical Center, HaSharon, Israel).




**Figure 1 legend:** P/F ratio, Ratio of arterial oxygen partial pressure (PaO<sub>2</sub>) to fractional inspired oxygen (FiO<sub>2</sub>); US, Ultrasound; CT, Computed tomography; NICaS, Non-Invasive Cardiac system; NO, Nitric oxide; TPA, Tissue plasminogen activator; ECMO, Extracorporeal membrane oxygenation; CRP, C-reactive protein; IP-10, interferon- $\gamma$  induced protein 10 (also known as CXCL-10); Plasm Abs, Plasm antibodies; TRAIL, TNF-related apoptosis inducing ligand.

**Figure 2:** IP-10 levels are significantly higher in viral infections associated with pulmonary pathology




**Figure 2 legend:** IP-10 levels in the non-ICU (n = 40) and ICU (n = 12) COVID-19 patients and IP-10 levels in healthy subjects (n = 98) and virally infected patients recruited in Curiosity<sup>14</sup> (NCT01917461) and Observer (NCT03011515) studies (n = 182) with PCR-confirmed viral infections including human rhinovirus (HRV), respiratory syncytial virus (RSV), influenza (Flu), and human coronavirus (HCoV). Each circle represents a patient. Black line corresponds to the group median and purple circle corresponds to group average. The box indicates patients with values between the 25 and 75 percentiles. The whiskers indicate patients with values between 2.5 and 97.5 percentiles. For the COVID-19 patients, IP-10 was measured using MeMed Key™ at multiple time points and the first IP-10 measurement is shown.

**Figure 3:** Mortality correlates with the number of days IP-10 >1000 pg/ml in SARS-CoV-2 positive patients (n = 52, upper panel) and among the subset of ICU patients (n = 12, lower panel).




**Figure 3 legend:** IP-10 was measured using MeMed Key™ at multiple time points during the SARS-CoV-2 positive patient's hospitalization. At least one IP-10 measurement  $\geq 1,000$  pg/ml in a given day was sufficient to classify as a day > 1,000 pg/ml. Each circle represents a patient; blue dots represent patients who survived and red dots represent patients who died. The cause of death of the ICU patient with a low number of days of IP-10 > 1,000 pg/ml was candidemia and of the non-ICU patient was metastatic breast cancer.

**Figure 4:** Initiation of corticosteroid therapy was reflected by a decrease in IP-10 levels (ICU patients, n = 12)



**Figure 4 legend:** IP-10 was measured using MeMed Key™ at the indicated time points during the stay of the patients in the ICU. Day 0 = initiation of corticosteroid therapy. Pink area indicates IP-10  $\geq$  1,000 pg/ml. Patients #2, #8 and #11 exhibited subsequent surges in IP-10 expression and are detailed in Figure 5.

**Figure 5:** IP-10 levels reflect personalized corticosteroid dosing (both increase and decrease)



**Figure 5 legend:** These 3 patients had a relapse of IP-10 levels >1,000 pg/ml, after initial treatment with corticosteroids. Right Y-axis shows the normalized<sup>25</sup> levels of corticosteroids administered

(hydrocortisone was converted to methylprednisolone). Left Y-axis shows the levels of IP-10 measured by MeMed Key™ at the indicated time points. X-axis shows the days from the first positive SARS-CoV-2 PCR. Lines connecting the doses indicate that the dose was given in each of the intervening day. Pink area indicates IP-10 > 1,000 pg/ml. Patient 2 survived, patients 8 and 11 died.

## SUPPLEMENTARY MATERIALS

### Supplementary Results

#### *Goal 1: Improve oxygen delivery*


Of the 12 ICU patients, nine patients had PEEP above 12 cm/H<sub>2</sub>O or oliguria or hypotension. Patient #3 displayed low cardiac index (2.2 L/minute) and D-dimers above 30,000 ng/ml and RV dysfunction; this patient was administered a mini dose of tissue plasminogen activator (TPA) but no improvement in oxygenation was observed and the patient died. Patient #2 also displayed low CO measurements (below 2.4 L/minute) and the echocardiography revealed RV dysfunction; this patient did not receive TPA due to mucosal bleeding. A bolus of intra-tracheal surfactant was administered and led to a transient improvement in oxygenation and the patient survived. All ICU patients exhibited elevated D-dimer levels above 1,000 ng/ml. Patient #7 developed colonic perforation with peritonitis and had small vessel thrombosis (in pathology) and a D-dimer level of 76,000 ng/ml.

**Supplementary Table 1:** Demographics of COVID-19 patients (total n = 52), IP-10 < 1,000 pg/ml (n = 33) and IP-10 > 1,000 pg/ml (n = 19)

		0<IP-10<=1000 (n=33)	1000<IP-10 (n=19)	p-value
General	Age	68.8 (21.5)	68.5 (14.2)	0.388
	Female	12 (36.0%)	4 (21.0%)	0.353
Smoking Status	Smoker	1 (3.0%)	2 (11.0%)	0.546
Other	Death	2 (6.0%)	2 (11.0%)	0.617
	Discharged	32 (97.0%)	19 (100.0%)	1
	Highest Temp	37.2 (1.0)	38.1 (1.3)	0.001
	Duration of Hospitalization	9.0 (13.8)	12.0 (15.0)	0.052
	Ventilated	6 (18.0%)	6 (32.0%)	0.317
	Time Ventilated	0.0 (0.0)	0.0 (12.5)	0.174
Co-infection	Bacterial Infection	4 (12.0%)	6 (32.0%)	0.142
	Fungal Infection	2 (6.0%)	2 (11.0%)	0.617
Conditions	Diabetes	13 (39.0%)	9 (47.0%)	0.771
	Cardiovascular Disease	7 (21.0%)	2 (11.0%)	0.458
	Cerebrovascular Disease	3 (9.0%)	0 (0.0%)	0.291
	Dyslipidemia	4 (12.0%)	5 (26.0%)	0.26
	Hypertension	11 (33.0%)	13 (68.0%)	0.021
	Hypothyroidism	2 (6.0%)	4 (21.0%)	0.175
	Malignancy	1 (3.0%)	4 (21.0%)	0.054
	Obesity (BMI>30 kg/m2)	7 (21.0%)	2 (11.0%)	0.458
Symptoms	Sore Throat	1 (3.0%)	0 (0.0%)	1
	Sputum Production	1 (3.0%)	0 (0.0%)	1
	Weakness	8 (24.0%)	4 (21.0%)	1
	Rhinorrhea	1 (3.0%)	0 (0.0%)	1
	Chest pain	2 (6.0%)	0 (0.0%)	0.527
	Diarrhea	4 (12.0%)	2 (11.0%)	1
	Dyspnea	12 (36.0%)	11 (58.0%)	0.157
	Fever	16 (48.0%)	13 (68.0%)	0.247
	Loss of Taste and Smell	4 (12.0%)	1 (5.0%)	0.641
	Cough	15 (45.0%)	11 (58.0%)	0.565
Markers	AST (GOT) (u/l) (max)	26.6 (35.2)	55.7 (37.9)	0.005
	ALT (GPT) (u/l) (max)	28.6 (46.1)	63.4 (85.1)	0.017
	Glucose (mg/dl) (max)	131.2 (110.8)	184.4 (150.3)	0.017
	LDH (u/l) (max)	491.0 (312.8)	689.0 (266.0)	0.011
	Lymph.abs (K/micl) (min)	0.9 (0.7)	0.5 (0.4)	0.004
	Neu.abs (K/micl) (max)	5.1 (3.8)	8.0 (8.5)	0.014
	PLT (10^3) (min)	229.0 (129.0)	162.0 (55.0)	0.013
	PaO2/FiO2 (min)	83.0 (63.0)	89.5 (46.5)	0.44
	Troponin (max)	12.0 (33.0)	25.0 (40.0)	0.059
	Urea (max)	34.6 (38.0)	58.0 (57.9)	0.002
	Ferritin (max)	449.4 (697.1)	901.0 (1147.6)	0.005
	D-Dimer (max)	1173.5 (2575.2)	2175.0 (6061.5)	0.055
	Creatinine (mg/dl) (max)	0.9 (0.4)	1.0 (0.4)	0.008
	Total Bilirubin (mg/dl) (max)	0.4 (0.4)	0.8 (0.6)	0.018
	Total Protein (g/dl) (max)	7.0 (0.7)	7.0 (0.7)	0.406
	CRP (max)	66.1 (82.3)	169.5 (109.0)	<0.001
Scores	COVID-19 severity	11 (33.0%)	15 (79.0%)	0.003
	qSOFA (on admission)	0.0 (1.0)	1.0 (1.0)	0.064
Treatments	Methylprednisolone	4 (12.0%)	8 (42.0%)	0.019
	Hydrocortisone	5 (15.0%)	5 (26.0%)	0.467
	Methylprednisolone+Prednisone+Hydrocortisone	10 (30.0%)	12 (63.0%)	0.04
	Renal Replacement Therapy	1 (3.0%)	1 (5.0%)	1
	Remdesivir	0 (0.0%)	1 (5.0%)	0.365
	Prednisone	3 (9.0%)	3 (16.0%)	0.656
	Nitric Oxide	2 (6.0%)	3 (16.0%)	0.342
	ECMO	1 (3.0%)	0 (0.0%)	1
	Vasopressors	5 (15.0%)	6 (32.0%)	0.181
	Convalescent Plasma	1 (3.0%)	6 (32.0%)	0.007
	Azithromycin	16 (48.0%)	19 (100.0%)	<0.001
	Antiviral Lopinavir/Ritonavir	0 (0.0%)	7 (37.0%)	<0.001
	Antiviral Hydroxychloroquine plus Azithromycin	14 (42.0%)	19 (100.0%)	<0.001
	Antiviral Hydroxychloroquine	17 (52.0%)	19 (100.0%)	<0.001
	Antibiotics	15 (45.0%)	15 (79.0%)	0.023
	Tocilizumab	5 (15.0%)	8 (42.0%)	0.047
	Days Under Systemic Corticosteroids	0.0 (3.0)	5.0 (10.5)	0.007
	First BV Test	TRAIL	58.2 (22.5)	50.7 (52.7)
CRP		38.4 (70.4)	107.4 (88.8)	<0.001
IP-10		333.2 (419.5)	1984.5 (1525.6)	<0.001


**Supplementary Table 1 Legend:** BMI, Body mass index; AST, Aspartate transaminase; AL, Alanine transaminase; LDH, Lactate dehydrogenase; Lymph. Abs, Absolute lymphocytes; Neu. Abs, Absolute neutrophils; PLT, platelets; PaO<sub>2</sub>/FiO<sub>2</sub>, Ratio of arterial oxygen partial pressure to fractional inspired oxygen; ECMO, Extracorporeal membrane oxygenation; qSOFA, quick sequential organ failure assessment; TRAIL, TNF-related apoptosis inducing ligand; IP-10, interferon- $\gamma$  induced protein 10 (also known as CXCL-10); CRP, C-reactive protein; BV Test, serum measurement of TRAIL, CRP and IP-10 performed using MeMed Key™.

**Supplementary Figure 1:** Mortality is not correlated with the number of days CRP > 90 mg/l (upper panel) or number of days ferritin > 500 mg/dl (lower panel) in the ICU patients (n = 12)



**Supplementary Figure 1 legend:** CRP and ferritin were measured at multiple time points during the 12 patient's stay in the ICU. At least one CRP > 90 mg/l or > 500 mg/dl in a given day was sufficient for the analysis. Each circle represents a patient; blue dots represent patients who survived (n = 9) and red dots represent patients who died (n = 3).

**Supplementary Figure 2:** Mortality is not correlated with the number of days IL-6 > 80 pg/ml (upper panel) or number of days IL-6 > 100 pg/ml (lower panel) in the ICU patients (n = 12)



**Supplementary Figure 2 legend:** IL-6 was measured at multiple time points during the 12 patient's stay in the ICU. At least one IL-6 > 80 pg/ml (upper panel) or IL-6 > 100 pg/ml in a given day was sufficient for the analysis. Each circle represents a patient; blue dots represent patients who survived (n = 9) and red dots represent patients who died (n = 3).